Getting Started with the FDA’s New LDT Rule
Experts explain what the phase-in process will look like—and how labs can get ahead of the game.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Experts explain what the phase-in process will look like—and how labs can get ahead of the game.
Though things appeared status quo in 2023, last year may prove to be a turning point for the laboratory industry.
An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
Labs, patients, and technology must all work together to deliver forward-thinking patient-centered care.
Robin Divine, MBA, president and CEO of TriCore Reference Laboratories, discusses key recent developments in the lab industry and predictions for 2024.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
Lisa-Jean Clifford of Gestalt Diagnostics, discusses key trends, challenges, and solutions in data analytics for clinical labs.
While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.